Strain Evaluation and Multi-Generational Stability of Cordyceps militaris for Functional Bioactive Compound Production.

IF 2.3 4区医学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY

Current drug metabolism Pub Date : 2026-04-14 DOI:10.2174/0113892002410536251027102107

Do Thi Gam, Truong Ngoc Minh, Nguyen Khac Hung, Nguyen Thuy Diep, Tran Thi Thuy, Kieu Thi Dung, Dang Thi Thanh Ha, Nguyen Thi Phuong Doai, Do Tien Phat, Tran Thi Huyen, Khuat Huu Trung

{"title":"Strain Evaluation and Multi-Generational Stability of Cordyceps militaris for Functional Bioactive Compound Production.","authors":"Do Thi Gam, Truong Ngoc Minh, Nguyen Khac Hung, Nguyen Thuy Diep, Tran Thi Thuy, Kieu Thi Dung, Dang Thi Thanh Ha, Nguyen Thi Phuong Doai, Do Tien Phat, Tran Thi Huyen, Khuat Huu Trung","doi":"10.2174/0113892002410536251027102107","DOIUrl":null,"url":null,"abstract":"Background: Cordyceps militaris is a medicinal fungus known for producing bioactive compounds, including cordycepin, adenosine, and polysaccharides, that exhibit antioxidant, immunomodulatory, and anticancer properties. Enhancing production and ensuring the genetic stability of these metabolites are essential for therapeutic development.Objective: To evaluate growth characteristics, metabolite yield, antioxidant activity, and genetic stability of 20 C. militaris strains, and to identify high-performing, stable candidates suitable for pharmaceutical applications.Methods: Twenty C. militaris strains were cultured and analyzed for colony diameter, fruiting body morphology, biomass yield, and bioactive compound content. Antioxidant activity was assessed using the DPPH assay. Genetic stability was monitored over five generations via MAT gene profiling.Results: Strain KTDT8 showed superior performance with the highest levels of cordycepin (469.8 ± 16.4 mg/100 g), adenosine (121.8 ± 7.4 mg/100 g), and polysaccharides (37.0 ± 2.9 mg/g), and the strongest antioxidant activity (IC₅₀ = 31.2 μg/mL). The strain maintained morphological and genetic stability across four generations, with a moderate decline in the fifth.Discussion: KTDT8 consistently demonstrated superior metabolite yield, antioxidant capacity, and morphological stability across generations. Despite a moderate decline in biomass and fruiting body quality in the fifth generation, the strain retained its core phenotypic and genetic traits. These findings support KTDT8 as a viable candidate for long-term cultivation and bioactive compound production.Conclusion: KTDT8 represents a genetically stable, high-yielding strain with strong antioxidant properties, supporting its potential for large-scale pharmaceutical and nutraceutical applications.","PeriodicalId":10770,"journal":{"name":"Current drug metabolism","volume":" ","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2026-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113892002410536251027102107","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Cordyceps militaris is a medicinal fungus known for producing bioactive compounds, including cordycepin, adenosine, and polysaccharides, that exhibit antioxidant, immunomodulatory, and anticancer properties. Enhancing production and ensuring the genetic stability of these metabolites are essential for therapeutic development.

Objective: To evaluate growth characteristics, metabolite yield, antioxidant activity, and genetic stability of 20 C. militaris strains, and to identify high-performing, stable candidates suitable for pharmaceutical applications.

Methods: Twenty C. militaris strains were cultured and analyzed for colony diameter, fruiting body morphology, biomass yield, and bioactive compound content. Antioxidant activity was assessed using the DPPH assay. Genetic stability was monitored over five generations via MAT gene profiling.

Results: Strain KTDT8 showed superior performance with the highest levels of cordycepin (469.8 ± 16.4 mg/100 g), adenosine (121.8 ± 7.4 mg/100 g), and polysaccharides (37.0 ± 2.9 mg/g), and the strongest antioxidant activity (IC₅₀ = 31.2 μg/mL). The strain maintained morphological and genetic stability across four generations, with a moderate decline in the fifth.

Discussion: KTDT8 consistently demonstrated superior metabolite yield, antioxidant capacity, and morphological stability across generations. Despite a moderate decline in biomass and fruiting body quality in the fifth generation, the strain retained its core phenotypic and genetic traits. These findings support KTDT8 as a viable candidate for long-term cultivation and bioactive compound production.

Conclusion: KTDT8 represents a genetically stable, high-yielding strain with strong antioxidant properties, supporting its potential for large-scale pharmaceutical and nutraceutical applications.

查看原文本刊更多论文

蛹虫草品系评价及功能性生物活性化合物生产的多代稳定性。

背景：蛹虫草是一种药用真菌，以产生生物活性化合物而闻名，包括虫草素、腺苷和多糖，这些化合物具有抗氧化、免疫调节和抗癌特性。提高生产和确保这些代谢物的遗传稳定性是必不可少的治疗发展。目的：评价20株军孢杆菌的生长特性、代谢产物产量、抗氧化活性和遗传稳定性，筛选出性能稳定、适合药用的候选菌株。方法：对20株双歧杆菌进行菌落直径、子实体形态、生物量和活性化合物含量的测定。采用DPPH法测定抗氧化活性。通过MAT基因谱监测五代遗传稳定性。结果：菌株KTDT8表现出优异的性能，虫草素（469.8±16.4 mg/100 g）、腺苷（121.8±7.4 mg/100 g）和多糖（37.0±2.9 mg/g）含量最高，抗氧化活性最强（IC₅₀= 31.2 μg/mL）。该菌株在4代中保持形态和遗传稳定性，在第5代中略有下降。讨论：KTDT8在几代之间始终表现出优越的代谢物产量、抗氧化能力和形态稳定性。尽管在第五代时生物量和子实体质量略有下降，但该菌株保持了其核心表型和遗传性状。这些发现支持KTDT8作为长期培养和生产生物活性化合物的可行候选者。结论：KTDT8是一种遗传稳定的高产菌株，具有较强的抗氧化性能，具有大规模制药和营养保健应用的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current drug metabolism 医学-生化与分子生物学

CiteScore

4.30

自引率

4.30%

发文量

审稿时长

4-8 weeks

期刊介绍： Current Drug Metabolism aims to cover all the latest and outstanding developments in drug metabolism, pharmacokinetics, and drug disposition. The journal serves as an international forum for the publication of full-length/mini review, research articles and guest edited issues in drug metabolism. Current Drug Metabolism is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the most important developments. The journal covers the following general topic areas: pharmaceutics, pharmacokinetics, toxicology, and most importantly drug metabolism. More specifically, in vitro and in vivo drug metabolism of phase I and phase II enzymes or metabolic pathways; drug-drug interactions and enzyme kinetics; pharmacokinetics, pharmacokinetic-pharmacodynamic modeling, and toxicokinetics; interspecies differences in metabolism or pharmacokinetics, species scaling and extrapolations; drug transporters; target organ toxicity and interindividual variability in drug exposure-response; extrahepatic metabolism; bioactivation, reactive metabolites, and developments for the identification of drug metabolites. Preclinical and clinical reviews describing the drug metabolism and pharmacokinetics of marketed drugs or drug classes.